The effect of a clinically practical exercise on levodopa bioavailability and motor response in patients with Parkinson disease

Giovanna Lopane, Manuela Contin, Cesa Scaglione, Fiorenzo Albani, Agostino Baruzzi, Paolo Martinelli

Research output: Contribution to journalArticle

Abstract

Objective: The aim of the study was to investigate the potential effect of short, moderate intensity (≤70% maximum heart rate) cyclette exercise on levodopa (LD)/dopa decarboxylase inhibitor bioavailability and motor response in a subgroup of Parkinson disease (PD) patients presenting a moderate-to-severe delay in fasting morning LD dose absorption and matched motor response. Methods: Ten patients underwent an oral LD instrumental kinetic-dynamic test based on simultaneous serial measurements of plasma LD concentrations, finger tapping motor effects, dyskinesia ratings plus Unified Parkinson Disease Rating Scale Motor Section (section III) evaluation after ingestion of their usual fasting first morning LD dose, on 2 occasions, 2 weeks apart, according to an intrasubject randomized cross-over design: once receiving their oral LD test dose immediately before a 15-minute cycling and once at seated rest. The main LD pharmacokinetic variables were time to peak, peak plasma concentration, and the area under the 4-hour plasma concentration-time curve. The main LD pharmacodynamic variables were the latency, duration of the motor effect elicited by the LD test dose, and the area under the 4-hour tapping effect-time curve. Results: The LD pharmacokinetics and pharmacodynamics did not differ between the 2 sessions. Conclusions: We found no significant effect of a moderate, clinically practical exercise on LD rate and extent of absorption and matched motor response in a subgroup of patients with delayed LD kinetic-dynamic effect.

Original languageEnglish
Pages (from-to)254-256
Number of pages3
JournalClinical Neuropharmacology
Volume33
Issue number5
DOIs
Publication statusPublished - Sep 2010

Fingerprint

Levodopa
Biological Availability
Parkinson Disease
Exercise
Fasting
Pharmacokinetics
Dopa Decarboxylase
Dyskinesias
Cross-Over Studies
Fingers
Eating
Heart Rate

Keywords

  • exercise
  • levodopa
  • pharmacodynamics
  • pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Clinical Neurology

Cite this

The effect of a clinically practical exercise on levodopa bioavailability and motor response in patients with Parkinson disease. / Lopane, Giovanna; Contin, Manuela; Scaglione, Cesa; Albani, Fiorenzo; Baruzzi, Agostino; Martinelli, Paolo.

In: Clinical Neuropharmacology, Vol. 33, No. 5, 09.2010, p. 254-256.

Research output: Contribution to journalArticle

@article{64cc683b6ce04e6f9210ba418084ca96,
title = "The effect of a clinically practical exercise on levodopa bioavailability and motor response in patients with Parkinson disease",
abstract = "Objective: The aim of the study was to investigate the potential effect of short, moderate intensity (≤70{\%} maximum heart rate) cyclette exercise on levodopa (LD)/dopa decarboxylase inhibitor bioavailability and motor response in a subgroup of Parkinson disease (PD) patients presenting a moderate-to-severe delay in fasting morning LD dose absorption and matched motor response. Methods: Ten patients underwent an oral LD instrumental kinetic-dynamic test based on simultaneous serial measurements of plasma LD concentrations, finger tapping motor effects, dyskinesia ratings plus Unified Parkinson Disease Rating Scale Motor Section (section III) evaluation after ingestion of their usual fasting first morning LD dose, on 2 occasions, 2 weeks apart, according to an intrasubject randomized cross-over design: once receiving their oral LD test dose immediately before a 15-minute cycling and once at seated rest. The main LD pharmacokinetic variables were time to peak, peak plasma concentration, and the area under the 4-hour plasma concentration-time curve. The main LD pharmacodynamic variables were the latency, duration of the motor effect elicited by the LD test dose, and the area under the 4-hour tapping effect-time curve. Results: The LD pharmacokinetics and pharmacodynamics did not differ between the 2 sessions. Conclusions: We found no significant effect of a moderate, clinically practical exercise on LD rate and extent of absorption and matched motor response in a subgroup of patients with delayed LD kinetic-dynamic effect.",
keywords = "exercise, levodopa, pharmacodynamics, pharmacokinetics",
author = "Giovanna Lopane and Manuela Contin and Cesa Scaglione and Fiorenzo Albani and Agostino Baruzzi and Paolo Martinelli",
year = "2010",
month = "9",
doi = "10.1097/WNF.0b013e3181f5328c",
language = "English",
volume = "33",
pages = "254--256",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - The effect of a clinically practical exercise on levodopa bioavailability and motor response in patients with Parkinson disease

AU - Lopane, Giovanna

AU - Contin, Manuela

AU - Scaglione, Cesa

AU - Albani, Fiorenzo

AU - Baruzzi, Agostino

AU - Martinelli, Paolo

PY - 2010/9

Y1 - 2010/9

N2 - Objective: The aim of the study was to investigate the potential effect of short, moderate intensity (≤70% maximum heart rate) cyclette exercise on levodopa (LD)/dopa decarboxylase inhibitor bioavailability and motor response in a subgroup of Parkinson disease (PD) patients presenting a moderate-to-severe delay in fasting morning LD dose absorption and matched motor response. Methods: Ten patients underwent an oral LD instrumental kinetic-dynamic test based on simultaneous serial measurements of plasma LD concentrations, finger tapping motor effects, dyskinesia ratings plus Unified Parkinson Disease Rating Scale Motor Section (section III) evaluation after ingestion of their usual fasting first morning LD dose, on 2 occasions, 2 weeks apart, according to an intrasubject randomized cross-over design: once receiving their oral LD test dose immediately before a 15-minute cycling and once at seated rest. The main LD pharmacokinetic variables were time to peak, peak plasma concentration, and the area under the 4-hour plasma concentration-time curve. The main LD pharmacodynamic variables were the latency, duration of the motor effect elicited by the LD test dose, and the area under the 4-hour tapping effect-time curve. Results: The LD pharmacokinetics and pharmacodynamics did not differ between the 2 sessions. Conclusions: We found no significant effect of a moderate, clinically practical exercise on LD rate and extent of absorption and matched motor response in a subgroup of patients with delayed LD kinetic-dynamic effect.

AB - Objective: The aim of the study was to investigate the potential effect of short, moderate intensity (≤70% maximum heart rate) cyclette exercise on levodopa (LD)/dopa decarboxylase inhibitor bioavailability and motor response in a subgroup of Parkinson disease (PD) patients presenting a moderate-to-severe delay in fasting morning LD dose absorption and matched motor response. Methods: Ten patients underwent an oral LD instrumental kinetic-dynamic test based on simultaneous serial measurements of plasma LD concentrations, finger tapping motor effects, dyskinesia ratings plus Unified Parkinson Disease Rating Scale Motor Section (section III) evaluation after ingestion of their usual fasting first morning LD dose, on 2 occasions, 2 weeks apart, according to an intrasubject randomized cross-over design: once receiving their oral LD test dose immediately before a 15-minute cycling and once at seated rest. The main LD pharmacokinetic variables were time to peak, peak plasma concentration, and the area under the 4-hour plasma concentration-time curve. The main LD pharmacodynamic variables were the latency, duration of the motor effect elicited by the LD test dose, and the area under the 4-hour tapping effect-time curve. Results: The LD pharmacokinetics and pharmacodynamics did not differ between the 2 sessions. Conclusions: We found no significant effect of a moderate, clinically practical exercise on LD rate and extent of absorption and matched motor response in a subgroup of patients with delayed LD kinetic-dynamic effect.

KW - exercise

KW - levodopa

KW - pharmacodynamics

KW - pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=77958001282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958001282&partnerID=8YFLogxK

U2 - 10.1097/WNF.0b013e3181f5328c

DO - 10.1097/WNF.0b013e3181f5328c

M3 - Article

C2 - 20852413

AN - SCOPUS:77958001282

VL - 33

SP - 254

EP - 256

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 5

ER -